First Bight
PORTFOLIO

Stephanie Culler, PhD

Co-Founder & CEO

Steve Van Dien, PhD

Co-Founder & CEO

Financing Round

Seed

Location

San Diego, CA

Company Website

Vertical(s)

Bio Tech
Health Care

Press Coverage

“Persephone Biosciences Closes $15M Seed Financing Round”

Read Story >>

***

“Persephone puts poop to work to explore and heal your gut microbiome”

Read Story >>

***

“Persephone Biosciences and Ginkgo Bioworks Announce Collaboration to Develop Novel Therapeutics”

Read Story >>

***

“Could Changes in Your Microbiome Increase Your Risk of Colorectal Cancer?”

Read Story >>

Significant Development(s)

ARGONAUT is the largest US study to map the gut and immune health of cancer patients. This project will unlock biomarkers for the development of therapeutics for the treatment and prevention of cancer.

About Persephone

Persephone is pioneering the use of synthetic biology for the development of microbial products that impact patient and infant health. Persephone is building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.